A Prospective Randomized Hoosier Oncology Trial of 5-Fluorouracil versus 5-Fluorouracil Plus Levamisole in the Treatment of Metastatic Colorectal Cancer
A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer
A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC)
A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer
A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer
Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC)
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer
A Multi-Center, Single Arm, Phase II study of Pembrolizumab (MK-3475) in Combination with Chemotherapy for Patients with Advanced Colorectal Cancer: HCRN GI14-186
A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
A Phase II Trial of Irinotecan (CPT-11), 5-Fluorouracil (5-FU), Glutamine, Leucovorin and Celecoxib as First Line Therapy for Metastatic Colorectal Cancer –GI00-2